Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Dec;2(4):217-223.
doi: 10.1007/BF00865279.

2-[2-[4-[2-[2-[ 1,3-Dihydro- 1,1-bis (4-hydroxyphenyl)-3-oxo-5-isobenzofuranthioureidyl]ethylaminocarbonyl]ethyl]phenyl] ethylamino]-5'- N-ethylcarboxamidoadenosine (FITC-APEC): A Fluorescent Ligand For A2a-Adenosine Receptors

Affiliations

2-[2-[4-[2-[2-[ 1,3-Dihydro- 1,1-bis (4-hydroxyphenyl)-3-oxo-5-isobenzofuranthioureidyl]ethylaminocarbonyl]ethyl]phenyl] ethylamino]-5'- N-ethylcarboxamidoadenosine (FITC-APEC): A Fluorescent Ligand For A2a-Adenosine Receptors

R Tyler McCabe et al. J Fluoresc. 1992 Dec.

Abstract

The fluorescein conjugate, FITC-APEC (2-[2-[4-[2-[2-[1,3-dihydro-l,l-bis(4-hydroxyphenyl)-3-oxo-5-isobenzofuranthioureidyl]ethylaminocarbonyl]ethyl]phenyl]ethylamino]-5'-N-ethylcarboxamidoadenosine), is a novel ligand derived from a series of functionalized congeners that act as selective A2a-adenosine receptor agonists. The binding of FITC-APEC to bovine striatal A2a,-adenosine receptors measured by fluorescence techniques was saturable and of a high affinity, with a Bmax, of 2.3 ± 0.3 pmol/mg protein and KD of 57 ± 2 nM. The KD value estimated by fluorescence was consistent with the Ki (11 ± 0.3 nM) obtained by competition studies with [3H]CGS 21680. Additionally, the Bmax, value found by FITC-APEC measurement was in agreement with Bmax, values obtained using radioligand binding. FITC-APEC exhibited rapid and reversible binding to bovine striatum. The potencies of chemically diverse A2a-adenosine receptor ligands estimated by inhibition of FITC-APEC binding were in good agreement with their potencies determined using radioligand binding techniques (r = 0.97, P = 0.0003). FITC-APEC binding was not altered by purine derivatives that do not recognize A2a-adenosine receptors. These findings demonstrate that the novel fluorescent ligand FITC-APEC can be used in the quantitative characterization of ligand binding to A2a-adenosine receptors.

Keywords: A2a-adenosine receptors; Fluorescence; bovine striatum; receptor binding.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Synthesis of the fluorescent A2a-adenosine receptor ligand, FITC-APEC.
Fig. 2
Fig. 2
Association and dissociation of FITC-APEC binding to bovine striatal membranes. Tissues were prepared and assayed as described under Materials and Methods. Association of FITC-APEC (50 nM) binding was performed by varying the incubation period (1–130 rain). Equilibrium was attained within 60 rain and maintained throughout the 130-rain duration. A 90-min incubation period was selected for use in subsequent experiments. Association data (■, solid line) represent means (mean % specific binding) from triplicate samples of two separate determinations. The rate constants were estimated using the equation k1 = (kobsk−1/LT, where LT is the total FITC-APEC concentration. The kobs and k1 estimates for FITC-APEC were 0.029 min −1 and 7.47 × 106 M−1 min−1, respectively. Dissociation of bound FITC-APEC was performed as described under Materials and Methods. The dissociation rate constant k−1 was 0.345 min−1 Dissociation data (□, dotted line) represent means (mean % specific binding) from triplicate samples of two separate experiments. The KD determined by nonequilibrium methods (KD = k−1/k1) was 46 nM.
Fig. 3
Fig. 3
Plot of a saturation isotherm constructed from equilibrium saturation data of FITC-APEC binding to bovine striatal membranes. The concentration of FITC-APEC was varied from 16 to 248 nM. Nonspecific binding was defined by the presence of 2-CADO (10 μM). Specific binding of FITC-APEC (50 mM) determined by fluorescence measurement was approximately 20% of the total binding (specific binding of [3H]CGS 21680 (6 nM) was determined to be approximately 50% of total binding). The isotherm is representative of three separate determinations. The KD and Bmax estimates for specific FITC-APEC binding determined using saturation isotherms were (mean ± SE) 57 ± 2 nM and 2.3 ± 0.3 pmol/mg protein, respectively. Data analysis was performed using GraphPAD (ISS Software, San Diego, CA). Inset: Representative Scatchard plot of saturation data.
Fig. 4
Fig. 4
Inhibition of specific FITC-APEC binding by A2a-adenosine receptor ligands. Inhibition of FITC-APEC binding (50 nM) to bovine striatal membranes was assessed as described under Materials and Methods. K1 values for inhibition of FITC-APEC binding in descending order of potency were as follows: NECA, 4.1 ± 0.1 nM (■); DPMA, 13 ± 3 nM (△, dotted line); 2-CADO, 34 ± 14 nM (•); and CV 1808, 131 ± 62 nM (□). Data (mean % specific binding) represent triplicate samples from at least three experiments. The competition curves demonstrate mass action displacement of FITC-APEC binding by the four compounds.
Fig. 5
Fig. 5
Correlation between the potencies of A2a-adenosine receptor ligands as inhibitors of FITC-APEC and radioligand binding. The K1 (nM) values assessed by inhibition of FITC-APEC binding (ordinate) by A2a-adenosine receptor ligands were related to K1 values found using [3H]NECA binding (abscissa). FITC-APEC inhibition data (means) were obtainted from the values in Fig. 4 and Table I. [3H]NECA inhibition data were from the report by Bruns et al. [23]. The following compounds were used in the graph: NECA, DPMA, 2-CADO, CHA, R-PIA, CV 1808, and theophylline. The correlation coefficient for inhibition of FITC-APEC binding versus [3H]NECA binding was r = 0.97 (P = 0.0003).

Similar articles

Cited by

References

    1. Yamamura HI, Enna SJ, Kuhar MJ. Neuro-transmitter Receptor Binding. Raven Press; New York: 1983.
    1. Snyder SH. JAMA. 1989;261:3126–3129. - PubMed
    1. McCabe RT, de Costa BR, Miller RL, Havunjian RH, Rice KC, Skolnick P. FASEB J. 1990;4:2934–2940. - PubMed
    1. Havunjian RH, de Costa BR, Rice KC, Skolnick P. J. Biol. Chem. 1990;265:22181–22186. - PubMed
    1. McCabe RT, Newman AH, Skolnick P. J. Pharmacol. Exp. Ther. 1992;262:734–740. - PubMed

LinkOut - more resources